falsefalse

Optimizing Frontline Treatment Approaches in EGFRm Metastatic NSCLC - Episode 6

Translating OS Data Into Patient Conversations: Balancing Benefit and Burden

,

Panelists discuss how explaining survival benefits to patients must be tailored to individual goals and expectations, with many patients having specific life milestones they hope to reach.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Communicating Survival Benefits and Treatment Trade-Offs

    Main Discussion Topics:

    • Strategies for explaining survival benefits to patients
    • Incorporating patient goals into treatment discussions
    • Avoiding preconceived notions about patient preferences based on age or other factors

    Key Points for Physicians:

    • Focus on patient-specific goals (eg, attending important life events) when discussing treatments
    • Recognize that patient preferences don’t always align with physician assumptions
    • Consider results from patient surveys that reveal preferences for quality of life over extended therapy

    Notable Insights:

    Data from a Chinese survey showed that over 70% of patients, family members, and doctors would prefer osimertinib monotherapy over combination therapy despite a 9-month delay in recurrence with the latter.

    Clinical Significance:

    Effective shared decision-making requires understanding individual patient goals and preferences rather than making assumptions based on demographic factors or physician biases.

    x